Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
about
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetesOnset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment.Once-weekly exenatide as a treatment for Type 2 diabetes.Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.Controlled release of biologics for the treatment of type 2 diabetes.Exenatide: pharmacokinetics, clinical use, and future directions.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonistsA Plethora of GLP-1 Agonists: Decisions About What to Use and When.Long-term studies of treatments for type 2 diabetes.Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
P2860
Q30249371-44F39422-AF27-45B7-B832-7F8DF97A39B1Q33708984-8D0D1238-BB50-4392-9B5B-BC6D8AAF5E63Q36023385-DA5F0ACA-14F4-4621-8BE3-F1B26F2C3830Q37561260-EE9819CB-179E-4E49-9B83-8B9EC709A562Q38392932-98E26198-61CD-4128-9F6A-0058DC3A6D95Q38497691-23E01811-AB41-4E22-982A-333E3B63DC8CQ38526870-BACA3604-91BE-4811-8494-9B9E86C2291EQ38587097-059C0382-1F14-4846-BA6A-9B22231D0531Q38602769-510041D4-F840-4D8E-825D-4269C1F4D6BCQ38665753-50466C94-881E-4639-8061-7156BC94954AQ38770746-9F62C405-EE0F-4F89-93F8-F9FD17C49AE0Q38866310-CDA20487-C8B3-4555-BD46-63A8467E22E7Q38885174-6484A82A-6BC8-46E4-803B-478812831644Q38987110-62B2787C-89C7-4C07-8397-333C6B5D5E1CQ39018646-2ECA7518-4565-4A82-A89A-43B50BA9CA86Q39489588-696BE991-6831-4B82-822D-127B4F148349Q40529883-F90B9DB2-D382-4538-AF2A-716963116FE9Q41551599-A51AE64A-218D-42B1-A3BA-175C8A2331FFQ47094551-929E7947-2517-4572-AD42-BD5E3E5CE4AAQ47386231-AC8B3855-91DF-4BBC-B9CF-BBE24CD6F3C5Q50963300-43D3E59F-9365-413C-9713-515E0081A269Q51249870-1C2180B7-904E-409E-9E34-19C91B9E9D97
P2860
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Five-year efficacy and safety ...... N-1 randomized clinical trial.
@ast
Five-year efficacy and safety ...... N-1 randomized clinical trial.
@en
type
label
Five-year efficacy and safety ...... N-1 randomized clinical trial.
@ast
Five-year efficacy and safety ...... N-1 randomized clinical trial.
@en
prefLabel
Five-year efficacy and safety ...... N-1 randomized clinical trial.
@ast
Five-year efficacy and safety ...... N-1 randomized clinical trial.
@en
P2093
P1476
Five-year efficacy and safety ...... ON-1 randomized clinical trial
@en
P2093
Carol H Wysham
David G Maggs
Leigh A MacConell
Michael E Trautmann
Peter S Griffin
P304
P356
10.1016/J.MAYOCP.2015.01.008
P407
P50
P577
2015-03-01T00:00:00Z